Su Shan, Wu Yi-Long
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China.
J Hematol Oncol. 2017 Aug 7;10(1):147. doi: 10.1186/s13045-017-0514-z.
With the development of evidence-based medicine, clinical trials have become necessary for investigating and validating the efficacy of new treatments. Over the past 10 years, several clinical trials of new anticancer agents have been designed and launched in China; this has greatly promoted the development of novel agents as well as of innovative clinical study designs. However, despite the significant advances made in clinical trials for novel agents, improvements are still required. In this mini-review, we will summarize the ongoing clinical trials of small molecular inhibitors for the treatment of lung cancer in China, aiming specifically to highlight the active involvement of China in these clinical studies. Furthermore, we will discuss the urgent need for improvement of clinical trials and anticancer agent research in China.
随着循证医学的发展，临床试验已成为研究和验证新治疗方法疗效的必要手段。在过去10年中，中国设计并开展了多项新型抗癌药物的临床试验；这极大地推动了新型药物以及创新临床研究设计的发展。然而，尽管新型药物的临床试验取得了显著进展，但仍有改进的空间。在本综述中，我们将总结中国正在进行的用于治疗肺癌的小分子抑制剂临床试验，特别旨在突出中国在这些临床研究中的积极参与。此外，我们还将讨论中国改进临床试验和抗癌药物研究的迫切需求。
